Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04432597CT.gov HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oropharyngeal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epinephrine (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 48 |
| Cyclophosphamide | HRYZ Biotech Co. | P2 | BB |
| Fludarabine | HRYZ Biotech Co. | P2 | BB |
| Pembrolizumab | Inhibrx Biosciences, Inc | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Loren Mell, MD | P2 | B |
| Young Til | National Cancer Institute (NCI) | P2 | B |
| Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
+15 more in the Oropharyngeal Carcinoma cohort
Other indications for Epinephrine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Disorder | — | P4 | BB · 68 |
| Crohn Disease | — | P4 | BB · 68 |
| Inflammatory Bowel Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epinephrine in Oropharyngeal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epinephrine-oropharyngeal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →